beclomethasone dipropionate + sodium fusidate

beclomethasone dipropionate + sodium fusidate is a topical combination therapy developed by Vanan Pharma. It consists of beclomethasone dipropionate, a potent synthetic glucocorticoid, and sodium fusidate, a narrow-spectrum antibiotic. Beclomethasone dipropionate acts as an anti-inflammatory and antipruritic agent by binding to glucocorticoid receptors, thereby modulating gene expression and inhibiting the release of inflammatory mediators. Sodium fusidate is a protein synthesis inhibitor that specifically targets bacterial elongation factor G (EF-G), preventing the translocation of the ribosome along the mRNA and thus halting bacterial growth. This combination is typically indicated for the treatment of inflammatory dermatoses, such as eczema or dermatitis, where a secondary bacterial infection is present or likely to occur.

Other names

Beclomethasone Dipropionate, Sodium Fusidate